Skip to main content
Sana Biotechnology, Inc. logo

Sana Biotechnology, Inc. — Investor Relations & Filings

Ticker · SANA ISIN · US7995661045 US Manufacturing
Open in API
Filings indexed 362 across all filing types
Latest filing 2024-09-25 Regulatory Filings
Country US United States of America
Listing US SANA

About Sana Biotechnology, Inc.

https://sana.com/

Sana Biotechnology, Inc. is a company that develops engineered cells as medicines to address the underlying causes of disease. Its core strategy involves two primary platforms: in vivo therapies designed to repair and control genes within a patient's existing cells, and ex vivo therapies that replace missing or damaged cells with new, functional ones. The company utilizes proprietary technologies, such as engineered fusogen proteins, for the targeted delivery of therapeutics. Sana's pipeline is focused on advancing drug candidates for a range of diseases, including diabetes, B-cell cancers, and B-cell related autoimmune disorders.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2024
Regulatory Filings
2024-09-25 English
Regulatory Filings 2024
Regulatory Filings
2024-09-24 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated September 6, 2024, reporting the resignation of an executive officer (Executive Vice President and Chief Financial Officer) effective October 4, 2024. The content focuses on a management change announcement, specifically the departure of a senior officer. There are no financial statements, earnings data, or other report types present. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is 2928 characters, which is short and focused solely on management change, confirming it is not a full report but a management information announcement.
2024-09-12 English
10-Q
Interim / Quarterly Report Q2 2024
2024-08-08 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 8, 2024, by Sana Biotechnology, Inc. It announces the issuance of a press release with financial results for the quarter ended June 30, 2024. The document explicitly states that the press release is attached as Exhibit 99.1 and that the information is being furnished, not filed, and is not incorporated by reference. The document itself is short (3541 characters) and primarily serves as an announcement of the earnings release rather than containing the financial results or detailed financial statements. According to the 'Menu vs Meal' rule, such a document is an announcement of a report (the earnings release) rather than the report itself. Therefore, the correct classification is Earnings Release (ER), as the document announces the initial quarterly financial results.
2024-08-08 English
PRIMARY DOCUMENT
Director's Dealing
2024-07-15 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.